Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin for DNMT3A Clonal Hematopoiesis in Acute Leukemia
NCT07188740Phase 1Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Aug 2026
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of liquid metformin (Aspargo Labs) in clonal hematopoiesis (CH), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Rate of major molecular response based on the variant-allele frequency (VAF) of DNMT3A R882 mutation at 6 months. Started Aug 2026; status: recruiting.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
clonal hematopoiesis (CH)
Beyond the preview
Go deeper on NCT07188740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07188740.